# US 2006/0154338 A1 · Novel antibiotic alternatives

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2006/0154338 A1
- Document ID: US20060154338A1
- Status: Published application
- Kind: A1
- Application number: 11/327,713
- Filed: 2006-01-06
- Published: 2006-07-13
- Earliest claimed: 2004-03-15
- Assignees: Iowa State University Research Foundation, Inc.
- Inventors: Chad Stahl
- Web page: https://patentgrep.com/patent/US20060154338A1

## CPC

- A61K 38/164: {from bacteria}
- A23K 20/147: Polymeric derivatives, e.g. peptides or proteins
- A23K 50/30: for swines
- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P 31/04: Antibacterial agents
- C07K 14/195: from bacteria
- C07K 14/245: Escherichia (G)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A23K: FODDER
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The present invention relates to two recombinant colicin expression systems, one utilizing a yeast expression system that produces a protein that is inexpensive to purify, and the other utilizing a plasmid expression system to be used as a probiotic culture. The recombinant colicins provide effective alternatives to conventional antibiotics and may be used to improve the efficiency of pork production, and the safety of its products.

## Claims

### Claim 1

An isolated expression vector construct for the production of a recombinant colicin comprising: (a) a DNA sequence encoding a colicin; and (b) DNA sequences allowing for the expression of the colicin.

### Claim 2 (depends on 1)

The vector of claim 1 wherein said vector is a plasmid based vector.

### Claim 3 (depends on 1)

The vector of claim 1 wherein said vector is a yeast based vector.

### Claim 4 (depends on 1)

The vector construct of claim 1 wherein the DNA sequence encoding the colicin is isolated from E. coli.

### Claim 5 (depends on 1)

The vector construct of claim 1 wherein the DNA sequence encoding the colicin is isolated from a pore-forming or a nuclease colicin.

### Claim 6 (depends on 1)

The vector construct of claim 1 whereby the colicin is selected from the group consisting of colicin A, colicin B, colicin E1, colicin Ia, and colicin N.

### Claim 7 (depends on 1)

The vector construct of claim 1 further including a promoter in reading frame with the coding sequence.

### Claim 8 (depends on 7)

The vector construct of claim 7 whereby the promoter is a yeast promoter.

### Claim 9 (depends on 7)

The vector construct of claim 7 whereby the promoter is selected from the group consisting of glyceraldehyde-3-phosphate dehydrogenase and alcohol oxidase 1.

### Claim 10 (depends on 7)

The vector construct of claim 7 whereby the promoter is a Lactobacilli promoter sequence.

### Claim 11 (depends on 10)

The vector construct of claim 10 whereby the promoter is upstream from the DNA sequence encoding the colicin.

### Claim 12 (depends on 1)

The vector construct of claim 1 further including a signal peptide in reading frame with the coding sequence.

### Claim 13 (depends on 12)

The vector construct of claim 12 whereby the signal peptide is an alpha-factor signal peptide of Sacchromyces cerevisiae.

### Claim 14 (depends on 13)

The vector construct of claim 13 whereby the signal peptide is upstream from the coding sequence for the colicin.

### Claim 15 (depends on 1)

A prokaryotic or eukaryotic host cell transformed strain transformed with the vector construct of claim 1.

### Claim 16 (depends on 14)

The cell of claim 14 that is a strain of P. pastoris.

### Claim 17 (depends on 16)

The cell of claim 16 that is Pichia pastoris.

### Claim 18 (depends on 1)

A recombinant colicin expressed by the vector construct of claim 1.

### Claim 19 (depends on 1)

A method for producing a recombinant colicin comprising: growing a bacterial or yeast strain transformed with a vector construct of claim 1 in a medium; and isolating the recombinant colicin.

### Claim 20 (depends on 19)

The method of claim 19 further including the step of purifying the recombinant colicin.

### Claim 21

A method of inhibiting the growth of pathogenic bacteria in animals comprising: introducing to an animal a bacterial growth inhibiting effective amount of a colicin.

### Claim 22 (depends on 21)

The method of claim 21 whereby the pathogenic bacteria is selected from one or more of the group consisting of E. coli, Salmonella, and Listeria.

### Claim 23 (depends on 21)

The method of claim 21 whereby the pathogenic bacteria is an enterohemorrhagic strain of E. coli.

### Claim 24 (depends on 23)

The method of claim 23 whereby the E. coli is selected from the group consisting of E. coli F4 and E. coli F18.

### Claim 25 (depends on 21)

The method of claim 21 whereby the colicin is selected from the group consisting of colicin A, colicin B, colicin E1, colicin Ia, and colicin N.

### Claim 26 (depends on 17, 21)

The method of claim 21 whereby the colicin is the recombinant colicin of claim 17.

### Claim 27 (depends on 21)

The method of claim 21 whereby the pathogenic bacteria is a Listeria strain selected from the group consisting of FSIS 1126, H7769, Scott A, H7768, and H7767.

### Claim 28

A method for the production of a colicin from a recombinant microorganism comprising: transforming a suitable host microorganism with one or more transformation cassettes each of which comprises a gene encoding a colicin, wherein the gene is introduced into the host microorganism; culturing the transformed host microorganism under suitable conditions; and recovering the colicin.

### Claim 29 (depends on 28)

The method of claim 28 wherein the suitable host microorganism is bacteria or yeast.

### Claim 30 (depends on 29)

The method of claim 29 wherein the suitable host microorganism is selected from the group consisting of Lactobacillus and Pichia spp.

### Claim 31 (depends on 28)

The method of claim 28 further including the step of purifying the recovered colicin.

### Claim 32

A host cell transformed with a gene encoding a colicin.

### Claim 33 (depends on 32)

The host cell of claim 32 whereby the gene encodes a pore-forming or a nuclease colicin.

### Claim 34 (depends on 31)

The host cell of claim 31 whereby the gene encodes a colicin selected from the group consisting of A, B, E1, 1a, and N.

### Claim 35

A method of reducing Listeria on food comprising: applying a colicin to the food.

### Claim 36 (depends on 35)

The method of claim 35 whereby the colicin is selected from the group consisting of A, B, E1, 1a, and N.

### Claim 37 (depends on 35)

The method of claim 35 whereby the colicin is applied to meat.

### Claim 38 (depends on 35)

The method of claim 35 whereby the colicin is recombinant.

### Claim 39

A method of reducing pathogenic bacteria on animal carcasses comprising: applying a colicin to an animal carcass.

### Claim 40 (depends on 39)

The method of claim 39 whereby the pathogenic bacteria is selected from one or more of the group consisting of E. coli and Salmonella.

### Claim 41 (depends on 39)

The method of claim 39 whereby the colicin is selected from the group consisting of A, B, E1, 1a, and N.

### Claim 42 (depends on 39)

The method of claim 39 whereby the colicin is recombinant.

### Claim 43

A method of reducing pathogenic bacteria in animals comprising: feeding the animal a colicin.

### Claim 44 (depends on 43)

The method of claim 43 whereby the colicin is selected from the group consisting of A, B, E1, 1a, and N.

### Claim 45 (depends on 43)

The method of claim 43 whereby the colicin is recombinant.

### Claim 46 (depends on 43)

The method of claim 43 whereby the pathogenic bacteria is selected from one or more of the group consisting of E. coli and Salmonella.
